BAY88-8223, Dose Finding Study in Patients With HRPC
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
Prostate Cancer|Neoplasm Metastasis
DRUG: Radium-223 dichloride (BAY88-8223)
Proportion of participants in each dose group with a confirmed PSA response, PSA response; each patient will be classified as PSA responder/non-responder according to the definition of PSA response:a decrease from baseline of at least 50% maintained for at least three weeks., 24 weeks, 12 months, 24 months
The maximum percent decrease in PSA level compared to baseline, 24 weeks, 12 months, 24 months|Time to PSA Progression, 24 weeks, 12 months, 24 months|Bone-ALP response (classified as for PSA response) and decrease in bone-ALP level compared to baseline, 24 weeks, 12 months, 24 months|Total number of SRE per patient, 24 weeks, 12 months, 24months|Pain Assessment and analgesic consumption, 24 weeks, 12 months, 24months|Time to death from first treatment, 24 weeks, 12 months, 24months|Time to Skeletal Related Events (SRE), 24 weeks, 12 months, 24 months|Adverse events, blood chemistry and haematological toxicity, 24 weeks, 12 months, 24 months
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.